David J. Mazzo, PhD
President and Chief Executive Officer
Dr. Mazzo is also a seasoned public and private company director having served on the boards of all the companies for which he was CEO plus Essex Chimie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals, EyePoint Pharmaceuticals (where he was Chairman of the Board) and Seneca Biopharma. He currently is the Chairman of the Board of Visioneering Technologies, Inc. (ASX:VTI), a developer and marketer of therapeutic contact lenses for pediatric myopia and presbyopia, and a Director of Feldan Therapeutics, a private company developing novel technology for the intracellular delivery of therapeutics.
Dr. Mazzo earned his Ph.D. in Analytical Chemistry as well as an M.S. in Chemistry at the University of Massachusetts (Amherst). He also holds dual degrees [B.S. in Chemistry and B.A. in Honors (Interdisciplinary Humanities)] from Villanova University. He complemented his American education as a Research Fellow at the Ecole Polytechnique Fédérale de Lausanne in Switzerland.
Robert Honigberg, MD
Interim Chief Medical Officer
Dr. Honigberg has over 30 years of clinical and medical leadership experience in pharmaceutical, device, digital and diagnostic companies. He has held Chief Medical Officer positions at GE Healthcare, Liposcience, and Ethicon Endo-Surgery at Johnson & Johnson. He has also held positions of medical leadership in clinical development, business development and medical affairs at Schering-Plough Oncology, Ortho Biotech, CardioDx, Flexion Therapeutics, Baxalta and Shire PLC. Robert also is a former Adjunct Professor of Health Enterprise Management at Kellogg Business School/Northwestern University. He also consults for MS&T Consulting and SSI Strategy.
Todd Girolamo, JD, MBA
Chief Legal Officer, SVP of Corporate Development and Corporate Secretary
Mr. Girolamo began his legal career as a corporate law associate at Cahill Gordon & Reindel and concluded his tenure in private practice at Reid & Priest where he gained expertise as a general commercial litigator practicing in the areas of intellectual property, securities law, employment law and bankruptcy. In addition to almost two decades of experience as both corporate counsel and private practitioner, Mr. Girolamo spent 12 years on Wall Street where he specialized in therapeutic healthcare equity securities at Oppenheimer & Co., CIBC World Markets, Leerink & Company and Summer Street Research Partners as a Series 24, 7 and 63 licensed principal. Subsequently he served as an analyst and portfolio manager at Lion’s Path Capital, managing a long-short portfolio of biopharma and med-tech equities.
Mr. Girolamo received a Bachelor of Arts from Harvard College, Juris Doctor from the University of Pennsylvania Law School and Master of Business Administration from Columbia Business School.
Vice President, Human Resources
Ms. Holler's background includes developing and leading global teams. She has driven organizational transformation efforts at Innophos Inc., a global specialty chemical company as VP of HR where she planned and executed organizational design and integration activity for mergers and acquisitions. In addition, she served as management liaison to the Compensation and Nominating and Governance Committees. Prior to Innophos, Ms. Holler served as Director of Organizational Effectiveness at Tata Consultancy Services where she was responsible for on-boarding, training and deployment of talent for the organization. Prior to that, Ms. Holler served as VP of HR at LifeCell Corporation where she established the HR organization and led the growth of the organization through succession planning, career development and recruitment of key talent. Prior to joining LifeCell, she was with Sanofi Aventis (and legacy companies) for 14 years where she held increasingly more responsible positions in global HR generalist capacities including HR Director for Global Drug Development and VP of HR, Global Dermatology.
Ms. Holler received a BA from the University of Delaware.
Gregory S. Berkin
Vice President, IT & Cybersecurity and Chief Information Officer
Before joining Caladrius, Greg held director and management roles in IT at other global & nationwide biotech companies including Regado Biosciences, Aeterna Zentaris, and Chugai Pharma USA.
Mr. Berkin has 25 years of experience in the technical profession with 20 years of unparalleled managerial experience, specializing in production systems, network engineering, facility operations, project management, hybrid cloud-computing, cybersecurity, and M&A activities. He currently serves as Co-Chair of the BioNJ IT & Cybersecurity committee as well as being an advisor to other organizations. Greg volunteers his time mentoring IT professionals from a career development perspective.
Greg holds a BA and MSc from Fairleigh Dickinson University.
John D. Menditto
Vice President, Investor Relations and Corporate Communications
Mr. Menditto has over 25 years of experience and specialization, particularly, in the areas of financial modeling, Regulation FD, corporate governance, investor targeting and capital raising. He has held senior roles at several healthcare and life science companies including Novartis Corporation, Medco Health Solutions and Argos Therapeutics. John has also spent a number of years as a senior communications consultant .
John is a former IR Magazine and PRSA/Big Apple award winner for his work in investor and corporate communications. He holds degrees in public relations and finance from Susquehanna University in Selinsgrove, Pennsylvania.
Vice President, Finance and Treasury
With over 25 years of experience in corporate finance, James has held various senior finance positions prior to Caladrius at OSI Pharmaceuticals, Inc., (acquired by Astellas) and Ciba Corporation (acquired by The BASF Group). James began his career at Ciba-Geigy (now Novartis Pharmaceuticals).
Mr. Nisco holds an MBA in Financial Management from Pace University and a Bachelor of Science in Business Economics from the State University of New York, College at Oneonta.